Eupraxia Pharmaceuticals Inc.

Biotechnology • Healthcare • Victoria, BC, United States • EPRX (NCM)

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

250 590 3968 2067 Cadboro Bay Road, Victoria, BC V8R 5G4, Canada

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

MarketBeat • Dec 13

Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why - Yahoo Finance

Yahoo Finance • Dec 4

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewswire

GlobeNewswire • Nov 4

Eupraxia Pharmaceuticals Stock Surges on Promising Drug News - TipRanks

TipRanks • Dec 11

Eupraxia Pharmaceuticals stock falls after pricing $70 million offering - Investing.com

Investing.com • Sep 23

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has EUPRAXIA PHARMACEUTICALS INC. had layoffs?

No layoff events have been recorded for EUPRAXIA PHARMACEUTICALS INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does EUPRAXIA PHARMACEUTICALS INC. have?

EUPRAXIA PHARMACEUTICALS INC. has approximately 33 employees.

What industry is EUPRAXIA PHARMACEUTICALS INC. in?

EUPRAXIA PHARMACEUTICALS INC. operates in the Biotechnology industry, within the Healthcare sector.

Is EUPRAXIA PHARMACEUTICALS INC. a publicly traded company?

Yes, EUPRAXIA PHARMACEUTICALS INC. is publicly traded under the ticker symbol EPRX on the NCM. The company has a market capitalization of approximately $0.39 billion.

Where is EUPRAXIA PHARMACEUTICALS INC. headquartered?

EUPRAXIA PHARMACEUTICALS INC. is headquartered in Victoria, BC, United States at 2067 Cadboro Bay Road, Victoria, BC V8R 5G4, Canada.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.